目的: 探讨阿德福韦酯联合灯盏细辛对慢性乙型肝炎肝纤维化的改善作用。方法: 将本院收治的慢
性乙肝肝纤维化病人125 例，随机分为2 组，治疗组( n = 63) 给予阿德福韦酯胶囊联合灯盏细辛注射液，对照组
( n = 62) 仅给予阿德福韦酯胶囊，2 组疗程均为30 d。比较2 组病人治疗前后肝功能、肝纤维化、血流动力学各指
标变化的差异，并统计不良反应。结果: 2 组病人治疗后ALT、AST、TBIL 水平均较治疗前显著改善( P＜0． 01) ，治
疗组GGT 水平较治疗前显著改善( P＜0． 01) ，而对照组治疗前后无显著改善，且治疗组治疗后肝功能各指标水
平均显著优于对照组( P＜0． 01) ; 2 组治疗后HA、LN、PcⅢ、cⅣ、全血黏度、血浆粘度、血细胞压积、血沉水平均较
治疗前显著改善( P＜0． 01) ，而治疗组治疗后各指标水平均显著优于对照组( P＜0． 05，P＜0． 01) 。2 组均未发现
明显不良反应。结论: 阿德福韦酯胶囊联合灯盏细辛注射液可显著改善慢性乙肝肝纤维化病人的肝功能、肝纤
维化以及血流动力学指标，且无明显不良反应，适合临床推广应用。

?Objective: To explore the improving effect of adefovir dipivoxil( ADV) combined with
Erigeron breviscapus on chronic hepatitis B with hepatic fibrosis． Methods: 125 cases of patients with
chronic hepatitis B and hepatic fibrosis were divided into two groups． The treatment group( n = 63) received
ADV capsule combined with Erigeron breviscapus injection，while the control group received
ADV capsule alone． The course of the two groups both lasted for 30 days． The differences of indexes of
liver function，hepatic fibrosis and haemodynamics in the two groups pre－and post－treatment were compared．
Results: The levels of ALT，AST，TBIL in the two groups post－treatment improved obviously than
that pre－treatment( P＜0． 01) ． The level of GGT in treatment group improved obviously than that pretreatment
( P＜0． 01) ，while there was no statistic difference pre－and post－treatment in control group．
The indexes of liver function in treatment group post－treatment were superior to that in control group
( P＜0． 01) ． The levels of HA，LN，PcⅢ，cⅣ，blood viscosity，plasma viscosity，haematocrit，ESR in the
two groups post－treatment all improved obviously than that pre－treatment( P＜0． 01) ，and the indexes
post－treatment in treatment group were superior to that in control group( P＜0． 05 or P＜0． 01) ． There
was no obvious adverse reaction in the two groups． Conclusion: ADV capsule combined with Erigeron
breviscapus injection can obviously improve the indexes of liver function，hepatic fibrosis and haemodynamics
in patients with chronic hepatitis B and hepatic fibrosis without obvious adverse reactions． It’s
suitable for clinical popularization and application．

R978． 7